Concepedia

Publication | Open Access

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

DOIFull Paper Access

27

Citations

0

References

2023

Year

Jennifer A. Chan, Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson,
Annals of Oncology

No additional data available for this publication yet. Check back later!